Retatrutide

GLP-1 / MetabolicResearch Use Only

Also known as: LY3437943, GGG tri-agonist, GIP/GLP-1/glucagon triple agonist

Retatrutide is an investigational triple receptor agonist targeting GIP, GLP-1, and glucagon receptors, commonly referenced in metabolic research literature. Studies describe its multi-pathway mechanism as a subject of active clinical investigation. It is frequently discussed alongside earlier single- and dual-agonist molecules.

Typical range (research)

Research literature commonly references escalating weekly amounts studied across roughly the ~1–12 mg/week range in trials

Half-life

~6 days

Route

Subcutaneous (research)

Common use

Metabolic and weight-management research

Common vial sizes

5 mg · 10 mg · 20 mg · 30 mg

Storage

Store lyophilized powder refrigerated (2–8°C) and protected from light; once reconstituted, keep refrigerated and use within the timeframe supported by stability data.

Stacking notes

Referenced in research as a single triple-agonist molecule; combining with other incretin agents is not standard in the literature.

Reported side effects

NauseaReduced appetiteGastrointestinal upsetIncreased heart rate (reported in trials)

Regulatory note: Investigational; not FDA-approved and not approved in Canada. Phase 3 trials ongoing. Research-grade material is not for human use.

Calculate a dose →

Dose figures are ranges commonly referenced in research literature, not recommendations or medical advice. Not for human or veterinary use. Consult a licensed physician.